Literature DB >> 28114506

Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis.

Katherine E Fero1, Taylor M Coe2, Paul T Fanta3, Chih-Min Tang4, James D Murphy5, Jason K Sicklick6.   

Abstract

Importance: There is a dearth of population-based evidence regarding outcomes of the adolescent and young adult (AYA) population with gastrointestinal stromal tumors (GISTs).
Objectives: To describe a large cohort of AYA patients with GISTs and investigate the effect of surgery on GIST-specific survival (GSS) and overall survival (OS). Design, Setting, and Participants: This retrospective cohort study of 392 AYA patients and 5373 older adult (OA) patients in the Surveillance, Epidemiology, and End Results (SEER) database with GISTs histologically diagnosed from January 1, 2001, through December 31, 2013, with follow-up through December 31, 2015, compared the baseline characteristics of AYA (13-39 years old) and OA (≥40 years old) patients and among AYA patients stratified by operative management. Kaplan-Meier estimates were used for OS analyses. Cumulative incidence functions were used for GSS analysis. The effect of surgery on survival was evaluated with a multivariable Fine-Gray regression model. Exposure: Tumor resection. Main Outcomes and Measures: GIST-specific survival and OS.
Results: This study included 392 AYA and 5373 OA patients diagnosed with GISTs (207 [52.8%] male AYA patients, 2767 [51.5%] male OA patients, 277 [70.7%] white AYA patients, and 3661 [68.1%] white OA patients). Compared with the OA patients, more AYA patients had small-intestine GISTs (139 [35.5%] vs 1465 [27.3%], P = .008) and were managed operatively (332 [84.7%] vs 4212 [78.4%], P = .003). Multivariable analysis of AYA patients found that nonoperative management was associated with a more than 2-fold increased risk of death from GISTs (subdistribution hazard ratio, 2.27; 95% CI, 1.21-2.25; P = .01). On subset analysis of 349 AYA patients with tumors of the stomach and small intestine, small-intestine location was associated with improved survival (OS: 91.1% vs 77.2%, P = .01; GSS: 91.8% vs 78.0%, P = .008). On subset analysis of 91 AYA patients with metastatic disease, operative management was associated with improved survival (OS: 69.5% vs 53.7%, P = .04; GSS: 71.5% vs 56.7%, P = .03). Conclusions and Relevance: This study found that AYA patients are more likely to undergo surgical management than OA patients. Operative management is associated with improved OS and GSS in AYA patients, including those with metastatic disease.

Entities:  

Mesh:

Year:  2017        PMID: 28114506      PMCID: PMC5560852          DOI: 10.1001/jamasurg.2016.5047

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  43 in total

1.  Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.

Authors:  Daniela Gasparotto; Sabrina Rossi; Maurizio Polano; Elena Tamborini; Erica Lorenzetto; Marta Sbaraglia; Alessia Mondello; Marco Massani; Stefano Lamon; Raffaella Bracci; Alessandra Mandolesi; Elisabetta Frate; Franco Stanzial; Jerin Agaj; Guido Mazzoleni; Silvana Pilotti; Alessandro Gronchi; Angelo Paolo Dei Tos; Roberta Maestro
Journal:  Clin Cancer Res       Date:  2016-07-07       Impact factor: 12.531

2.  National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.

Authors:  Archie Bleyer; Michael Montello; Troy Budd; Scott Saxman
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors:  Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

4.  Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.

Authors:  Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

5.  Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

Authors:  C Mussi; U Ronellenfitsch; J Jakob; E Tamborini; P Reichardt; P G Casali; M Fiore; P Hohenberger; A Gronchi
Journal:  Ann Oncol       Date:  2009-07-23       Impact factor: 32.976

6.  A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis.

Authors:  Teresa M Neuhann; Veit Mansmann; Sabine Merkelbach-Bruse; Barbara Klink; Achim Hellinger; Heinz-Gert Höffkes; Eva Wardelmann; Hans-Ulrich Schildhaus; Sigrid Tinschert
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

7.  Gastric stromal tumors. Reappraisal of histogenesis.

Authors:  M T Mazur; H B Clark
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

8.  Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA.

Authors:  Taylor M Coe; Katherine E Fero; Paul T Fanta; Robert J Mallory; Chih-Min Tang; James D Murphy; Jason K Sicklick
Journal:  J Gastrointest Surg       Date:  2016-03-29       Impact factor: 3.452

Review 9.  The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.

Authors:  C A Stratakis; J A Carney
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

Review 10.  Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.

Authors:  Jason K Sicklick; Nicole E Lopez
Journal:  J Gastrointest Surg       Date:  2013-06-18       Impact factor: 3.452

View more
  10 in total

1.  SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors.

Authors:  Jeffrey A Norton; Teresa Kim; Joseph Kim; Martin D McCarter; Kaitlyn J Kelly; Joyce Wong; Jason K Sicklick
Journal:  J Gastrointest Surg       Date:  2017-08-14       Impact factor: 3.452

Review 2.  Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Authors:  Pushpa Neppala; Sudeep Banerjee; Paul T Fanta; Mayra Yerba; Kevin A Porras; Adam M Burgoyne; Jason K Sicklick
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

3.  Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value?

Authors:  Francis Esposito; Joan Maurel
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-07

4.  Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.

Authors:  Yi-Cheng Wu; Ping-Tao Tseng; Yu-Kang Tu; Chung-Yao Hsu; Chih-Sung Liang; Ta-Chuan Yeh; Tien-Yu Chen; Che-Sheng Chu; Yutaka J Matsuoka; Brendon Stubbs; Andre F Carvalho; Saho Wada; Pao-Yen Lin; Yen-Wen Chen; Kuan-Pin Su
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

5.  A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.

Authors:  Lindsey M Charo; Adam M Burgoyne; Paul T Fanta; Hitendra Patel; Juliann Chmielecki; Jason K Sicklick; Michael T McHale
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 6.  Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients.

Authors:  Monika Dudzisz-Śledź; Anna Klimczak; Elżbieta Bylina; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

Review 7.  Current treatment strategies in pediatric gastrointestinal stromal cell tumor.

Authors:  Brent A Willobee; Hallie J Quiroz; Matthew S Sussman; Chad M Thorson; Juan E Sola; Eduardo A Perez
Journal:  Transl Gastroenterol Hepatol       Date:  2018-08-08

8.  Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Chun-Jun Li; Jia Chen; Yu-Zhou Qin; Jian-Si Chen; Wei-Zhong Tang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

9.  Patient demographics, clinicopathologic features, and outcomes in wild-type gastrointestinal stromal tumor: a national cohort analysis.

Authors:  Tahsin M Khan; Emily A Verbus; Alexander J Rossi; Jonathan M Hernandez; Jeremy L Davis; Brian A Coakley; Andrew M Blakely
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.996

10.  Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study.

Authors:  Lei Yue; Yingchao Sun; Mengjia Hu; Weiling Hu
Journal:  Biomed Res Int       Date:  2022-09-07       Impact factor: 3.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.